Validation of specific mitophagy biomarkers across Alzheimer's disease continuum
Published
| Region | Prague |
|---|---|
| Title of the Programme | Research |
| Title of the Project | Validation of specific mitophagy biomarkers across Alzheimer's disease continuum |
| Project Website | |
| Number of the Project | TO01000215 |
| Project Promoter | Univerzita Karlova |
| Project Partner from Donor State | University of Oslo |
| Czech Partner | N/A |
| Status | Estimated project duration: 1/ 2021 - 4/ 2024 |
| Total Eligible Costs | 1 403 615 EUR |
| Grant | 1 258 865 EUR |
Project description:
The project aims to develop early diagnostic biomarkers of Alzheimer disease (AD) by validating a series of new biomarkers in serum and cerebrospinal fluid (CSF) in participants from the Czech Brain Aging Study (CBAS).
This Czech–Norwegian joint project will involve researchers from CBAS - Czech team with a unique clinical cohort and a top Norwegian research team specialized in mitophagy research. We aim to:
- Determine changes of designated mitophagy proteins in serum and CSF of AD individuals compared to non-AD and cognitively normal controls;
- Determine the relation to demographics, cognitive status and standard AD biomarkers;
- Verify the findings from CBAS on induced pluripotent stem cells and animal models;
- Validate specific mitophagy proteins as early diagnostic marker of AD.